Advertisement

Advertisement

2023 NCCN Annual Congress: Hematologic Malignancies

By Chase Doyle / January 25, 2024 / 2023 NCCN Annual Congress: Hematologic Malignancies

ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy

Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged...

By Chase Doyle / November 25, 2023 / 2023 NCCN Annual Congress: Hematologic Malignancies

Optimizing Treatment Selection for Newly Diagnosed and Secondary AML: Focus on Cytogenetic and Molecular Data

Greater understanding of biological disease factors in acute myeloid leukemia (AML) has led to more effective and personalized treatment options. At the 2023 National Comprehensive Cancer Network (NCC...

Advertisement

Advertisement

Nov

21

Today In Oncology

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis Monitoring and Treatment

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

Advertisement

© 2024 HSP News Service, L.L.C.